The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients. PharmaLedger will serve as a single source of truth for the healthcare ecosystem and will be designed for efficient decentralized governance, wide adoption by the stakeholders of the ecosystem, compliance with extant and emerging standards and regulation, and end-to-end connectivity and interoperability. Sustainability of the platform will be ensured by leveraging existing, successful blockchain technologies; open source reference implementation; and a fully documented, actionable methodology for evolutionary digitization of the healthcare industry. The project will address the key challenges of the healthcare ecosystem through prioritized delivery of applications and validation of business use cases, including but not be limited to end-to-end product tracking for combating counterfeit medicines and medical supplies; supply chain integrity; efficiency of recruitment and submission in clinical trials; and machine-learning health data marketplaces. The platform will support integrated use of medical devices across the use cases. The PharmaLedger project brings together 28 partners from 10 EU Member States, including 11 large pharmaceutical companies; highly innovative technology SMEs specializing in blockchain development, security, privacy and business intelligence; universities and research institutes specializing in pharmacoeconomic analysis, research of patient requirements, big data analytics and electronic health records; leading clinical trials companies; supply chain partners; patient representatives; and leading healthcare service providers.

More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached. AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses demen-tia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform. The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical cen-tres, who closely collaborate with 3 SMEs contributing unique technologies, an established data govern-ance body, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia pre-diction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of phar-maceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.